

Freedom of Information Request	FOI 21-356	15 th September 2021
--------------------------------	------------	---------------------------------

Q1. How many patients has your trust treated (for any disease) in the last 6 months with the following treatments:

- **Doptelet (avatrombopag)**
- **Jakavi (ruxolitinib)**
- **Nplate (romiplostim)**
- **Revolade (eltrombopag)**
- **Tavlesse (fostamatinib)**
- **Hydroxycarbamide**

Please see the attached report. Please note the Health Board is unable to provide patients numbers and we have therefore provided the information by quantities dispensed.

Q2. In the last 6 months, how many patients has your trust treated for:

- **Immune thrombocytopenia (ICD10 code D69.3)**
21 patients with a primary diagnosis of ITP were treated as an inpatient or day case from January to June 2021.
- **Myelofibrosis (ICD10 code D47.4)**
3 patients with a primary diagnosis of Myelofibrosis were treated as an inpatient or day case from January to June 2021.
- **Myelofibrosis (ICD10 code D47.4) – patients over the age 65**
3 patients over the age of 65, with a primary diagnosis of Myelofibrosis, were treated as an inpatient or day case from January to June 2021.

Q3. Of the patients treated for immune thrombocytopenia (ICD10 code D69.3) in the last 6 months, how many were treated with:

- **Mycophenolate mofetil**
Please see the attached report. Please note the Health Board is unable to provide patients numbers and we have therefore provided the information by quantities dispensed.
- **Rituximab**
As above.
- **Surgery (splenectomy)**
Of the patients treated for ITP in the last 6 months (Q2), none were treated with a splenectomy.

Q4. How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years?

- **Of the myelofibrosis patients diagnosed in the last 3 years, how many were treated in the past 6 months with Hydroxycarbamide?**
21 patients with a primary diagnosis of myelofibrosis were treated as an inpatient or day case in the last 3 years to June 2021. It is not possible to

show if these patients were diagnosed within the last three years. This figure does not include those patients diagnosed and treated in Primary Care and outpatient setting.

- **Of the myelofibrosis patients diagnosed in the last 3 years, how many have received no active treatment in the past 6 months?**

As above.

Q5. Does your trust participate in any ongoing clinical trials for immune thrombocytopenia (ITP)? If so, can you please provide the name of each trial along with the number of patients taking part?

The Health Board is taking part in the UKAITPR study (United Kingdom Adult Idiopathic Thrombocytopenic Purpura (ITP) Registry: An Investigation of Disease Progression, Treatment Effectiveness, and Co-morbid Conditions). 110 patients have been recruited from the Health Board.

Q6. Does your trust participate in any ongoing clinical trials for myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part?

The Health Board has just opened a 'Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination with Ruxolitinib in Subjects with Myelofibrosis (REFINE)'. No recruitment has been made to date.